A recent study revealed that some recurrent gliomas were hypermutated and harbored driver mutations in the RB and Akt-mTOR pathways that bore the signature of temozolomide-induced mutagenesis after adjuvant temozolomide chemotherapy. Here, MTOR is linked to glioma.